This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Warns About Naproxen

Updated from 8:26 a.m. EST

There's more pain for drugmakers and new worries for drug users.

The Food and Drug Administration is now warning about heart risks related to the use of naproxen, a long-time popular pain killer sold over the counter, as well as a prescription-strength medication sold under various names.

The latest shock to the industry came Monday night when federal regulators disclosed that the National Institutes of Health last Friday halted a drug study testing whether certain anti-inflammatory drugs could reduce the risk of patients contracting Alzheimer's disease. The drugs were being tested in people 70 years of age or older who were considered to be at increased risk because of family history, but did not have symptoms of the disease.

The study compared Naproxen vs. Celebrex, which is made by Pfizer (PFE - Get Report). The best-known over-the-counter version of the drug Naproxen is Aleve.

The Alzheimer's disease test was halted partly because another clinical study involving Celebrex showed that the Pfizer drug increased the risk of cardiovascular problems among patients who took high doses, a development that Pfizer disclosed last Friday and which triggered a selloff in the company's share price. The test, sponsored by the National Cancer Institute, was determining if Celebrex could prevent certain colon polyps that are a precursor to colon cancer.

But this Alzheimer's disease test, called ADAPT, was also halted because it "indicated an apparent increase in cardiovascular and cerebrovascular events" among naproxen patients vs. patients receiving a placebo, the NIH said Monday night.

The test was stopped "as a precautionary measure to ensure the safety of the study's participants," said NIH Director Dr. Elias A. Zerhouni. "The investigators made their decision based on the risk/benefit analysis specific to this trial." The ADAPT trial began in 2001 and was conducted at six U.S. sites. Approximately 2400 volunteer participants were randomly assigned to receive naproxen, Celebrex or a placebo for a time up to three years.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
MRK $52.98 0.86%
PFE $31.97 1.95%
AAPL $112.34 4.29%
FB $89.89 3.05%
GOOG $614.34 2.77%


Chart of I:DJI
DOW 16,351.38 +293.03 1.82%
S&P 500 1,948.86 +35.01 1.83%
NASDAQ 4,749.9790 +113.8740 2.46%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs